Bruker Corporation
BRKRBruker Corporation (BRKR) is a global leader in scientific instrumentation and analytical solutions. It specializes in high-performance tools for molecular and materials research, including mass spectrometry, nuclear magnetic resonance (NMR), and other analytical techniques. The company's products are widely used in healthcare, pharmaceuticals, academia, and industrial research to support scientific discovery and quality control.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| July 7, 2026 | $0.05 | 2026-06-22 | 2026-06-22 |
| April 7, 2026 | $0.05 | 2026-03-23 | 2026-03-23 |
| January 2, 2026 | $0.05 | 2025-12-08 | 2025-12-08 |
| October 3, 2025 | $0.05 | 2025-09-23 | 2025-09-23 |
| June 27, 2025 | $0.05 | 2025-06-16 | 2025-06-16 |
Dividends Summary
- Consistent Payer: Bruker Corporation has rewarded shareholders with 42 dividend payments over the past 10 years.
- Total Returned Value: Investors who held BRKR shares during this period received a total of $1.86 per share in dividend income.
- Latest Payout: The most recent dividend of $0.05/share was paid 11 days ago, on July 7, 2026.
- Yield & Schedule: BRKR currently pays dividends quarterly with an annual yield of 0.34%.
- Dividend Growth: Since 2016, the dividend payout has grown by 25.0%, from $0.04 to $0.05.
- Dividend Reliability: BRKR has maintained or increased its dividend for 42 consecutive payments.
Company News
The global mass spectrometry market is valued at $6.68 billion in 2025 and is projected to reach $14.09 billion by 2035, growing at a CAGR of 7.74%. Growth is driven by pharmaceutical manufacturing, omics research, clinical diagnostics, and precision medicine adoption. North America leads the market while Asia Pacific records the fastest growth a...
The global spatial genomics and transcriptomics market is projected to grow from USD 0.60 billion in 2025 to USD 1.90 billion by 2035 at a 12.23% CAGR. Growth is driven by increased adoption of AI-powered spatial biology technologies, precision medicine initiatives, and high-resolution molecular profiling in oncology and translational research. N...
The omics-based clinical trials market is experiencing robust growth, expanding from $31.71 billion in 2025 to $34.49 billion in 2026 with an 8.8% CAGR, and projected to reach $47.78 billion by 2030. Growth is driven by increasing demand for personalized medicine, genomics advancements, AI-enabled patient recruitment, and biomarker-driven trial d...
Markets traded cautiously on Tuesday despite benign inflation data (CPI at 2.7% YoY, core CPI at 2.6%) that supported Fed rate cut expectations. Silver surged 4.5% to $89/oz amid supply concerns. Major indices remained flat with the S&P 500 near record highs. Earnings results were mixed: JPMorgan fell 3% on weak investment banking fees, Delta sli...
Lane Generational, a Massachusetts-based investment advisor, completely sold its $3.6 million stake in Bruker during Q3 2025, exiting all 87,607 shares amid the company's challenging market performance.
